Chromogranin A as an Alternative to 5-Hydroxyindoleacetic Acid in the Evaluation of Symptoms during Treatment of Patients with Neuroendocrine Tumors

Publisher： Karger

E-ISSN： 1423-0194|89|3|296-301

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.89, Iss.3, 2008-10, pp. : 296-301

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chromogranin A Is a Reliable Biomarker for Gastroenteropancreatic Neuroendocrine Tumors in an Asian Population of Patients

By  

Neuroendocrinology, Vol. 95, Iss. 4, 2012-02 ,pp. : 344-350

Karger

Access to resources Recommend Favorite

Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity

By  

Neuroendocrinology, Vol. 103, Iss. 3-4, 2015-08 ,pp. : 345-353

Karger

Access to resources Recommend Favorite

Chromogranin A in Diagnosing and Monitoring Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Large Series from a Single Institution

By  

Neuroendocrinology, Vol. 100, Iss. 2-3, 2014-11 ,pp. : 240-249

Karger

Access to resources Recommend Favorite

ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

By  

Neuroendocrinology, Vol. 103, Iss. 2, 2016-01 ,pp. : 153-171

Karger

Access to resources Recommend Favorite

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors

By  

Neuroendocrinology, Vol. 90, Iss. 2, 2009-08 ,pp. : 214-219

Karger

Access to resources Recommend Favorite